scholarly journals Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study

2008 ◽  
Vol Volume 4 ◽  
pp. 1407-1416 ◽  
Author(s):  
Toivo Laks ◽  
Keba ◽  
Leiner ◽  
Euro Merilind ◽  
Mall Petersen ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Open Label ◽  
High Risk Patients ◽  
Parallel Group ◽  
Risk Patients ◽  
Multi Center Study ◽  
Center Study ◽  
Real Clinical Practice

scholarly journals Terms of admission to the hospital and performing endovascular procedures in patients with acute myocardial infarction without ST segment elevation in real clinical practice

2020 ◽  
Vol 11 (3) ◽  
pp. 10-15
Author(s):  
Ionatan R. Rafaeli ◽  
Alexandra Iu. Kireeva ◽  
Irina E. Chernysheva ◽  
Igor Y. Kostyanov ◽  
Nino V. Tsereteli ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Endovascular Procedures ◽  
Time Interval ◽  
Time Intervals ◽  
St Segment Elevation ◽  
High Risk Patients ◽  
St Segment ◽  
Risk Patients ◽  
Real Clinical Practice

Aim. To find out the relationship of the severity of patients condition, with acute myocardial infarction without ST segment elevation (NSTEMI), upon admission to the hospital on the basis of the Global Registry of Acute Coronary Events (GRACE) scale with the time interval between the onset of the disease and up to hospitalization (painhospitalization), and to clarify the effect of the GRACE score on the time interval to endovascular procedures (EVP) doorballoon, in real clinical practice. Material and methods. The study included 421 NSTEMI patients. Patients were admitted between 2000 and 2017. All patients underwent coronary angiography followed by EVP. Depending on the clinical condition, at admitted to the hospital, patients were divided into risk groups on the GRACE scale. According to the indicators painhospitalization and doorballoon 3 time intervals were allocated: 6 hours, 624 and 24 hours. Results. At admission, 73.9% (311) patients had an average and high risk on the GRACE scale. Patients with high risk were significantly more often (49.6%) hospitalized during the first 6 hours after onset of the disease than later (p0.05). 2/3 of all patients and 3/4 of patients with high risk had the time interval of painhospitalization up to 24 hours. 51.8% patients in the total group and 65.8% among high-risk patients had a doorballoon interval up to 6 hours. During first 24 hours after hospitalization EVP was successfully completed on 90.7% of patients. One patient had a fatal outcome. At discharge none of the patients were observed the symptoms of angina pectoris and congestive heart failure. Conclusion. In the all group, according to the allocated time intervals painhospitalization, patients were distributed practically equally. The severity of the condition of the studied patients is indicated by the fact that almost 3/4 of them had a high and average risk on the GRACE scale. It is encouraging that in the first 6 hours from the onset of the disease, high-risk patients were significantly more often hospitalized. Almost 2/3 of high-risk patients and more than half of all patients had a doorballoon indicator-up to 6 hours. It is important that in the first 24 hours, successful EVP was performed in 90.7% of patients. Thus, our results (low mortality, absence of angina and heart failure after EVP) indicate the correct management and treatment of NSTEMI patients, which is close to the latest world recommendations, comes from real life circumstances and can be recommended for real clinical practice.

scholarly journals Prevention of Hypotension following Spinal Anaesthesia in Caesarean Section - then and now

2012 ◽  
Vol 8 (4) ◽  
pp. 415-419
Author(s):  
J K Mitra
Keyword(s):  
Risk Factors ◽  
Clinical Practice ◽  
High Risk ◽  
Caesarean Section ◽  
Spinal Anaesthesia ◽  
Limited Data ◽  
First Line ◽  
High Risk Patients ◽  
Risk Patients ◽  
Poor Efficacy

Hypotension during spinal anaesthesia for caesarean section remains a common scenario in our clinical practice. Certain risk factors play a role in altering the incidence of hypotension. Aortocaval compression counteraction does not help to prevent hypotension. Intravenous crystalloid prehydration has poor efficacy; thus, the focus has changed toward co-hydration and use of colloids. Phenylephrine is established as a first- line vasopressor, although there are limited data from high-risk patients. Ephedrine crosses the placenta more than phenylephrine and cause possible alterations in the foetal physiology.http://dx.doi.org/10.3126/kumj.v8i4.6242 Kathmandu Univ Med J 2010;8(4):415-19   

scholarly journals Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 393
Author(s):  
Alexander Hendricks ◽  
Anu Amallraja ◽  
Tobias Meißner ◽  
Peter Forster ◽  
Philip Rosenstiel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
High Risk ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Standard Of Care ◽  
High Risk Patients ◽  
Risk Patients ◽  
Individualized Treatments ◽  
Colorectal Cancer Patients

Personalized treatment vs. standard of care is much debated, especially in clinical practice. Here we investigated whether overall survival differences in metastatic colorectal cancer patients are explained by tumor mutation profiles or by treatment differences in real clinical practice. Our retrospective study of metastatic colorectal cancer patients of confirmed European ancestry comprised 54 Americans and 54 gender-matched Germans. The Americans received standard of care, and on treatment failure, 35 patients received individualized treatments. The German patients received standard of care only. Tumor mutations, tumor mutation burden and microsatellite status were identified by using the FoundationOne assay or the IDT Pan-Cancer assay. High-risk patients were identified according to the mutational classification by Schell and colleagues. Results: Kaplan–Meier estimates show the high-risk patients to survive 16 months longer under individualized treatments than those under only standard of care, in the median (p < 0.001). Tumor mutation profiles stratify patients by risk groups but not by country. Conclusions: High-risk patients appear to survive significantly longer (p < 0.001) if they receive individualized treatments after the exhaustion of standard of care treatments. Secondly, the tumor mutation landscape in Americans and Germans is congruent and thus warrants the transatlantic exchange of successful treatment protocols and the harmonization of guidelines.

Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice

2019 ◽  
Vol 287 ◽  
pp. e212
Author(s):  
U. Kassner ◽  
T. Hollstein ◽  
F. Schumann ◽  
T. Grenkowitz ◽  
H. Scharnagl ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Proprotein Convertase ◽  
High Risk Patients ◽  
Risk Patients

PCSK9-Inhibitor treatment of cardiovascular high risk patients in clinical practice – New data regarding safety and effectivity

2018 ◽  
Vol 275 ◽  
pp. e31
Author(s):  
T. Hollstein ◽  
T. Grenkowitz ◽  
H. Scharnagl ◽  
W. März ◽  
E. Steinhagen-Thiessen ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
High Risk Patients ◽  
Pcsk9 Inhibitor ◽  
Risk Patients ◽  
Inhibitor Treatment

scholarly journals Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (11) ◽  
pp. e0142033 ◽  
Author(s):  
Anne-Els van de Logt ◽  
Charles H. Beerenhout ◽  
Hans S. Brink ◽  
Jos J. van de Kerkhof ◽  
Jack F. Wetzels ◽  
...  
Keyword(s):  
Cohort Study ◽  
High Risk ◽  
Membranous Nephropathy ◽  
Idiopathic Membranous Nephropathy ◽  
Open Label ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A

Blood ◽  
2013 ◽  
Vol 122 (11) ◽  
pp. 1954-1962 ◽  
Author(s):  
Corien L. Eckhardt ◽  
Alice S. van Velzen ◽  
Marjolein Peters ◽  
Jan Astermark ◽  
Paul P. Brons ◽  
...  
Keyword(s):  
Clinical Practice ◽  
High Risk ◽  
Factor Viii ◽  
Hemophilia A ◽  
Factor Viii Gene ◽  
Inhibitor Development ◽  
High Risk Patients ◽  
Key Points ◽  
Risk Patients

Key Points The inhibitor incidence in nonsevere hemophilia A patients with certain F8 mutations approaches the inhibitor incidence in severe patients. These findings are highly relevant for clinical practice, as they facilitate identification of high-risk patients based on F8 genotype.

Sign in / Sign up

Export Citation Format

Share Document